Quarterly Result12 Nov 2025, 09:35 pm
HealthCare Global Enterprises Ltd Reports Q2 & H1FY26 Financial & Business Update: Revenue up by 169% and 163% respectively
AI Summary
HealthCare Global Enterprises Ltd (HCG), a leading provider of cancer care in India, announced its financial results for the quarter and half year ended 30th September 2025. The company reported a significant increase in revenue, adjusted EBITDA, and profit after tax for both Q2FY26 and H1FY26. The growth was driven by strong performance across key geographies and improved cost efficiencies. The company also reported an increase in OPD footfall, chemo sessions administered, and LINAC capacity utilizations. HCG is expanding its operations and investing in advanced molecular diagnostics and organoid-based platforms to enable drug discovery and targeted therapies tailored to Indian genetic diversity.
Key Highlights
- Revenue up by 169% in Q2FY26 and 163% in H1FY26
- Adjusted EBITDA increased by 184% in Q2FY26 and 193% in H1FY26
- Profit after tax stood at Rs. 163 Mn in Q2FY26 and Rs. 210 Mn in H1FY26
- OPD footfall, chemo sessions administered, and LINAC capacity utilizations increased
- Company is investing in advanced molecular diagnostics and organoid-based platforms